To gauge who's doing a decent job, Market Strategies earlier this year surveyed 500 primary care physicians who evaluated 14 big drugmakers and found that a favorable image can pay dividends - higher prescribing; greater willingness to try new products; interest in making time to read literature or attend programs; and readiness to make time for sales reps or medical liaisons. (Here is an excerpt).
Which drugmaker keeps a doc's time to a minimum? Merck. Which drugmaker's PAP eats up the most time? Schering-Plough. As for flexbility, Merck finished first again, while Sanofi-Aventis pulled up the rear. But when it comes to trust, Pfizer was the winner. The loser? Roche.